Publication Date:
2013-07-04
Description:
Key Points AML induction with liposomal daunorubicin (80 mg/m2 per day for 3 days) shows antileukemic activity comparable to idarubicin (12 mg/m2 per day for 3 days). Liposomal daunorubicin promises to be more active in the t(8;21) subgroup and causes less treatment-related toxicity.
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine